Sintx Technologies Inc Stock Price, News & Analysis

SINTX (NASDAQ: SINT) announced a USPTO Notice of Allowance for a method patent covering its antipathogenic fibrous materials and cited a recently issued U.S. patent No. 12,433,356 (Oct 7, 2025) for the composition. Together, the composition and method patent families expand IP coverage across medical textiles, wound dressings, filtration/PPE, and high-touch clinical surfaces.

The company cites laboratory data showing up to ~99.97% reduction of infectious SARS-CoV-2 in minutes and estimates an addressable market of ~$30B across targeted segments. SINTX plans licensing and co-development deals leveraging both materials and process claims.

SINTX Technologies (NASDAQ: SINT) received a U.S. Patent Notice of Allowance for method claims covering its antipathogenic fabric technology on Oct 14, 2025, expanding IP protection beyond the composition patent (U.S. Patent No. 12,433,356, granted Oct 7, 2025).

This dual patent coverage—composition plus method—targets medical textiles, wound dressings, filtration/PPE and high-touch clinical surfaces and supports licensing and co-development across the company's estimated $30B total addressable market. Company-cited lab data report up to ~99.97% SARS-CoV-2 reduction in minutes for silicon nitride materials; the release notes these are lab results and not cleared device indications. SINTX will pursue licensing, partnerships, and commercialization leveraging the broader IP estate.

SINTX Technologies (NASDAQ: SINT), a company specializing in biomedical applications of silicon nitride, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025 in New York City.

CEO Eric Olson will outline the company's growth strategy, discuss near-term milestones, and explain the impact of their silicon nitride platform in medical device and infection-prevention markets. The presentation will also cover recent financial initiatives, including their warrant inducement plan.

SINTX Technologies (NASDAQ: SINT), a biomedical ceramics company, has announced the successful exercise of warrants resulting in $3.8 million in gross proceeds. The transaction involves the immediate exercise of warrants to purchase 1,099,431 shares at $3.32 per share, originally issued in February 2025.

In exchange for the exercise, the company will issue new unregistered warrants for 1,649,147 shares with an exercise price of $4.79 per share, exercisable immediately with a 5.5-year expiration. H.C. Wainwright & Co. serves as the exclusive placement agent, and SINTX plans to use the proceeds for working capital purposes.

SINTX Technologies (NASDAQ: SINT) has received a USPTO Notice of Allowance for its "Antipathogenic Fibrous Materials" patent application, marking a crucial milestone for its silicon nitride-based antipathogen platform. The patent provides broad protection for using silicon nitride in multiple applications targeting the $30 billion global infection-prevention market.

The technology has demonstrated remarkable efficacy, achieving ~99.97% reduction of multiple coronavirus lineages within 10 minutes and complete inactivation by 30 minutes in laboratory tests. The patent enables applications across medical devices, surgical care, wound management, filtration, PPE, and healthcare infrastructure, addressing the critical challenge of healthcare-associated infections (HAIs) that affect 1 in 31 U.S. hospital patients.

SINTX plans to pursue strategic partnerships and licensing agreements for commercialization, targeting immediate opportunities in wound dressings, surgical drapes, and high-touch clinical environments, with longer-term applications in implant coatings and filtration media.

SINTX Technologies (NASDAQ: SINT) has published groundbreaking research demonstrating its silicon nitride (Si₃N₄) material's powerful antiviral properties against multiple virus strains, including SARS-CoV-2 and MERS-CoV. The study showed up to 99.97% reduction in SARS-CoV-2 within 10 minutes of contact.

As the only FDA-cleared and ISO-certified silicon nitride manufacturer in the U.S., SINTX is targeting the infection-prevention market, estimated to reach $230 billion by 2032. The company aims to commercialize applications in wound care, surgical equipment, PPE, and medical textiles. Silicon nitride offers advantages over traditional antimicrobials, being non-toxic to mammalian cells while effectively neutralizing pathogens.

SINTX Technologies (NASDAQ: SINT), a leader in silicon nitride ceramics for medical devices, has announced significant strategic developments following its acquisition of SiNAPTIC Surgical in July 2025. The company has undergone major restructuring, including leadership expansion and operational streamlining.

Key developments include the successful implantation of over 50,000 spinal interbody devices through CTL/Amedica partnership, and expansion of their product portfolio with 510(k)-cleared interbody spinal implants and pending approval for foot and ankle fusion wedges. The company has strengthened its leadership team with the addition of four key executives from SiNAPTIC.

SINTX has divested non-core assets, including the sale of TA&T subsidiary and closure of its armor ceramics facility, to focus on high-margin medical device opportunities. Despite a slight revenue decrease in Q2 2025, this aligns with their strategic exit from low-margin OEM manufacturing.

SINTX Technologies (NASDAQ: SINT) has announced a breakthrough in biomaterial development, publishing a peer-reviewed study validating silicon nitride (Si₃N₄) surface coatings on carbon fiber-reinforced polyetherketoneketone (CFR-PEKK) trauma plates. The research, supported by NIH-NIAMS and conducted with Drexel University, demonstrates successful integration of silicon nitride into 3D-printed continuous carbon fiber PEKK composites.

The study revealed two key achievements: the hybrid-manufactured CFR-PEKK trauma plates matched the mechanical stiffness of cortical bone, and the Si₃N₄ coating maintained mechanical performance while potentially offering enhanced osseointegration and antimicrobial properties. This development expands SINTX's biomaterial platform into additively-manufactured polymer-carbon-ceramic constructs, with potential applications in orthopedic trauma, spine, and custom surgical implants.

SINTX Technologies (NASDAQ: SINT) has submitted a 510(k) premarket notification to the FDA for its innovative silicon nitride osteotomy wedges, marking its entry into the $750.5 million foot and ankle fusion market. The company's proprietary silicon nitride (Si₃N₄) technology has already been used in over 50,000 spinal interbody fusion devices since 2008.

The new implants offer key advantages including pro-osteogenic properties, antimicrobial capabilities without additives, and superior radiographic clarity. SINTX's solution combines advanced biomaterial science with disposable instrumentation, targeting a market expected to reach $1.38 billion by 2032.

This strategic launch follows SINTX's recent acquisition of SiNAPTIC Surgical on July 1, 2025, positioning the company for significant revenue growth in both hospital and ambulatory surgery center settings.